Definitive Healthcare (NASDAQ:DH) Updates Q3 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its third quarter earnings guidance on Monday. The company provided earnings per share guidance of $0.07-0.08 for the period, compared to the consensus earnings per share estimate of $0.09. The company issued revenue guidance of $61.0-62.5 million, compared to the consensus revenue estimate of $63.51 million.

Definitive Healthcare Price Performance

Shares of NASDAQ:DH traded down $0.15 on Monday, hitting $3.55. The stock had a trading volume of 1,298,598 shares, compared to its average volume of 806,107. The company has a market capitalization of $418.67 million, a price-to-earnings ratio of -2.01, a price-to-earnings-growth ratio of 4.58 and a beta of 1.30. The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.30 and a current ratio of 2.30. The firm’s 50 day moving average price is $5.44 and its 200-day moving average price is $7.03. Definitive Healthcare has a twelve month low of $3.19 and a twelve month high of $11.47.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Tuesday, May 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.04). Definitive Healthcare had a positive return on equity of 0.51% and a negative net margin of 78.16%. The business had revenue of $63.48 million during the quarter, compared to analyst estimates of $64.00 million. On average, equities research analysts predict that Definitive Healthcare will post 0.09 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Stifel Nicolaus cut their price objective on shares of Definitive Healthcare from $9.50 to $7.50 and set a buy rating on the stock in a report on Wednesday, July 31st. Morgan Stanley lowered Definitive Healthcare from an overweight rating to an equal weight rating and cut their target price for the company from $11.50 to $9.00 in a research note on Wednesday, May 8th. Barclays decreased their target price on Definitive Healthcare from $7.00 to $6.00 and set an equal weight rating for the company in a research report on Wednesday, July 31st. Needham & Company LLC reiterated a hold rating on shares of Definitive Healthcare in a research report on Wednesday, July 31st. Finally, Robert W. Baird decreased their price objective on shares of Definitive Healthcare from $8.00 to $6.00 and set a neutral rating for the company in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Definitive Healthcare has a consensus rating of Hold and a consensus price target of $8.45.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.